Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedTech’s New Normal: More Regulatory, Pricing Pressures And Challenging Financing Climate

This article was originally published in The Gray Sheet

Executive Summary

Sustaining innovation in the current policy and financing environment may require new strategies from device companies focused not just on developing new products but on expanding into new kinds of offerings, including services and “holistic” solutions, Ernst & Young concludes in a recent report.

You may also be interested in...

MedTech M&A Surge Continues In 2011 Following 95% Jump In 2010

Merger and acquisition activity among U.S. and European medical technology firms roughly doubled in 2010 to a total of $30.6 billion and remained heated through the first half of 2011, according to a report from consulting firm Ernst & Young.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts